Elevance Health director Ramiro G. Peru acquired 1,000 common shares on November 19, 2026, at a weighted average price of $383.86. The Form 4 filed on November 20 reports 11,908 Elevance shares held directly after the purchase.
What the Form 4 says about price and ownership
The filing lists code P for the acquisition. A footnote says Peru made the purchase in multiple trades priced from $383.62 to $383.92 per share. Multiplying the reported average by 1,000 yields approximately $383,860. The average is a transaction figure, separate from any closing quote for Elevance (NYSE ELV).
The reported position implies 10,908 directly held shares immediately before the purchase. On that base, the 1,000 shares increased the direct position by about 9.2%. The transaction appears in the common stock table. The filing leaves the box for a prearranged trading plan unchecked.
What shareholders can read alongside the purchase
In its October 21 third quarter results, Elevance reported diluted earnings of $6.27 per share and adjusted diluted earnings of $6.99. The company said its results included a net nonoperating benefit of $1.85 per share. The financial filing explains that benefit. Peru’s Form 4 establishes the size of his purchase and does not state his reasons for making it.
See more FOLITIC Insider Trading coverage. The photograph shows an Anthem office in California from before the Elevance name change.
Sources Ramiro Peru’s Elevance Health Form 4 · Elevance Health third quarter release.
Cover photograph by Eeekster via Wikimedia Commons, CC BY SA 3.0.



